Pathway Health is an integrated healthcare company that provides advanced products and services to patients suffering from chronic pain and related conditions. The Company owns and operates nine community-based clinics across four provinces where its team of health professionals work together to help patients through a variety of evidence-based approaches and products, including medical cannabis. Pathway's patient care programs utilize an interdisciplinary approach that is guided by trained pain specialists, physical and occupational therapists, psychologists, nurses, and other healthcare providers. Pathway is also the leading provider of medical cannabis services in Canada and has established itself as the collaboration partner with national and regional pharmacy companies for the delivery of medical cannabis services to their customers. The Company is working with several pharmacy companies on the development of Cannabis Health Products (CHPs) for OTC distribution through retail pharmacy locations across the country following anticipated changes to the Cannabis Act.
At Pathway Health, we are committed to delivering personalized care to help improve a patients’ quality of life. We strive to provide patients with timely access to personalized treatment plans using advanced and clinically-proven solutions to achieve the best outcomes.
Global Crossing Airlines provides an investor update on their operations in August 2021. They discuss their FAA certification progress, current and pending charter contracts domestically and internationally, marketing initiatives through their Flugy platform, growing human capital, plans for their Jetlines spin-off, cargo operations, and developing a new airline headquarters and maintenance facility. The update contains forward-looking statements and financial projections that are subject to risks and uncertainties that could cause actual results to differ materially.
Pathway Health is one of the largest providers of out-of-hospital pain management services in . The Company owns and operates 9 community-based clinics across 4 provinces where its team of health professionals work together to help patients through a variety of evidence-based approaches. Pathway Health's patient care programs utilize an interdisciplinary approach that is guided by trained pain specialists, physical and occupational therapists, psychologists, nurses, and other healthcare providers. Pathway Health has also developed an expertise in harm reduction where medicinal cannabis is being used as an alternative to traditional opioids.
This document contains an investor presentation for an organization providing chronic pain services and medical cannabis telehealth. It discusses the company's growth from $600k in 2018 revenue to $12.6 million in 2020, its network of 9 pain clinics across Canada, and plans for expansion. It also outlines the company's proprietary digital platform, pharmacy initiatives including pharmacist education and patient referrals, and financial overview showing its sources of revenue. The document contains numerous disclaimers regarding forward-looking statements and risks involved in the company's projections.
Global Crossing Airlines - September 1st 2021 Investor Update WebinarThe Howard Group Inc.
Global Crossing Airlines Group Inc. was incorporated under the laws of British Columbia and continued as a Federal
corporation pursuant to the Canada Business Corporations Act effective February 28, 2017. On February 5, 2020, the
Company entered into a definitive agreement with Global Crossing Airlines, Inc. (“Global USA”), a Delaware
corporation, with respect to a business combination of the Company and Global USA (the “Transaction”). On
December 22, 2020, the Company changed its jurisdiction of incorporation from the Province of British Columbia,
Canada to the State of Delaware (the “U.S. Domestication“). In connection with the U.S. domestication, the Company
changed its name to “Global Crossing Airlines Group, Inc.”
The Company’s principal business activity is the start-up of an aircraft, crew, maintenance, insurance (“ACMI”) and
wet lease US charter airline serving the US, Caribbean and Latin American markets. The address of the Company’s
registered office is office is c/o Cogency Global Inc., 850 New Burton Rd, Suite 201, Dover, County of Kent, Delaware
19904. The Company’s shares trade on the TSX Venture Exchange under the symbol “JET” and are quoted on the
OTCQB under the symbol “JETMF”.
About Canada Jetlines Operations Ltd.
Canada Jetlines is a 100-per-cent-equity-financed and well-capitalized leisure carrier, which will utilize a growing fleet of Airbus 320 aircraft targeting a start in early 2022, subject to Canadian Transport Agency and Transport Canada approval. The carrier was created to provide Canadian consumers with more value choices and travel options to fly to coveted sun and leisure destinations in the United States, the Caribbean and Mexico. With a projected growth of 15 aircraft by 2025, Canada Jetlines aims to offer the best-in-class operating economics, customer comfort and fly-by-wire technology, providing an elevated guest-centric experience from the first touch point. The carrier will use a state-of-the-art Web booking platform, making the turnkey solution available to travel agents, tour operators and consumers, with the capability of generating revenue on reservations and ancillary sales. The efficient aircraft design, merged with the experience of the all-Canadian management team, allows for accessible flight options without sacrificing quality or convenience.
Canada Jetlines is a 100% equity financed and well capitalized low-cost tour and charter leisure carrier that will utilize a growing fleet of Airbus 320 aircraft to service popular sun destinations starting in early 2022, subject to Canadian Transport Agency and Transport Canada approval.
For more information about everything Canada Jetlines, please visit www.jetlines.ca.
Global Crossing is a U.S. 121 domestic flag and supplemental airline flying the Airbus A320 family aircraft. GlobalX flies as an ACMI (aircraft, crew, maintenance and insurance) and charter airline serving the U.S., Caribbean and Latin American markets.
At Pathway Health, we are committed to delivering personalized care to help improve a patients’ quality of life. We strive to provide patients with timely access to personalized treatment plans using advanced and clinically-proven solutions to achieve the best outcomes.
Global Crossing Airlines provides an investor update on their operations in August 2021. They discuss their FAA certification progress, current and pending charter contracts domestically and internationally, marketing initiatives through their Flugy platform, growing human capital, plans for their Jetlines spin-off, cargo operations, and developing a new airline headquarters and maintenance facility. The update contains forward-looking statements and financial projections that are subject to risks and uncertainties that could cause actual results to differ materially.
Pathway Health is one of the largest providers of out-of-hospital pain management services in . The Company owns and operates 9 community-based clinics across 4 provinces where its team of health professionals work together to help patients through a variety of evidence-based approaches. Pathway Health's patient care programs utilize an interdisciplinary approach that is guided by trained pain specialists, physical and occupational therapists, psychologists, nurses, and other healthcare providers. Pathway Health has also developed an expertise in harm reduction where medicinal cannabis is being used as an alternative to traditional opioids.
This document contains an investor presentation for an organization providing chronic pain services and medical cannabis telehealth. It discusses the company's growth from $600k in 2018 revenue to $12.6 million in 2020, its network of 9 pain clinics across Canada, and plans for expansion. It also outlines the company's proprietary digital platform, pharmacy initiatives including pharmacist education and patient referrals, and financial overview showing its sources of revenue. The document contains numerous disclaimers regarding forward-looking statements and risks involved in the company's projections.
Global Crossing Airlines - September 1st 2021 Investor Update WebinarThe Howard Group Inc.
Global Crossing Airlines Group Inc. was incorporated under the laws of British Columbia and continued as a Federal
corporation pursuant to the Canada Business Corporations Act effective February 28, 2017. On February 5, 2020, the
Company entered into a definitive agreement with Global Crossing Airlines, Inc. (“Global USA”), a Delaware
corporation, with respect to a business combination of the Company and Global USA (the “Transaction”). On
December 22, 2020, the Company changed its jurisdiction of incorporation from the Province of British Columbia,
Canada to the State of Delaware (the “U.S. Domestication“). In connection with the U.S. domestication, the Company
changed its name to “Global Crossing Airlines Group, Inc.”
The Company’s principal business activity is the start-up of an aircraft, crew, maintenance, insurance (“ACMI”) and
wet lease US charter airline serving the US, Caribbean and Latin American markets. The address of the Company’s
registered office is office is c/o Cogency Global Inc., 850 New Burton Rd, Suite 201, Dover, County of Kent, Delaware
19904. The Company’s shares trade on the TSX Venture Exchange under the symbol “JET” and are quoted on the
OTCQB under the symbol “JETMF”.
About Canada Jetlines Operations Ltd.
Canada Jetlines is a 100-per-cent-equity-financed and well-capitalized leisure carrier, which will utilize a growing fleet of Airbus 320 aircraft targeting a start in early 2022, subject to Canadian Transport Agency and Transport Canada approval. The carrier was created to provide Canadian consumers with more value choices and travel options to fly to coveted sun and leisure destinations in the United States, the Caribbean and Mexico. With a projected growth of 15 aircraft by 2025, Canada Jetlines aims to offer the best-in-class operating economics, customer comfort and fly-by-wire technology, providing an elevated guest-centric experience from the first touch point. The carrier will use a state-of-the-art Web booking platform, making the turnkey solution available to travel agents, tour operators and consumers, with the capability of generating revenue on reservations and ancillary sales. The efficient aircraft design, merged with the experience of the all-Canadian management team, allows for accessible flight options without sacrificing quality or convenience.
Canada Jetlines is a 100% equity financed and well capitalized low-cost tour and charter leisure carrier that will utilize a growing fleet of Airbus 320 aircraft to service popular sun destinations starting in early 2022, subject to Canadian Transport Agency and Transport Canada approval.
For more information about everything Canada Jetlines, please visit www.jetlines.ca.
Global Crossing is a U.S. 121 domestic flag and supplemental airline flying the Airbus A320 family aircraft. GlobalX flies as an ACMI (aircraft, crew, maintenance and insurance) and charter airline serving the U.S., Caribbean and Latin American markets.
GlobalX is a US 121 domestic flag and supplemental airline flying the Airbus A320 family aircraft. GlobalX has one A320 in revenue operations and has begun the process to add its A321 aircraft onto its certificate subject to FAA and DOT approvals. GlobalX has announced the delivery of its third and fourth aircraft deliveries in the second half of 2021. GlobalX flies as an ACMI and wet lease charter airline serving the US, Caribbean, and Latin American markets. For more information, please visit www.globalxair.com
Global Crossing Airlines (GlobalX) Investor Presentation - TSXV: JET / OTCQB:...The Howard Group Inc.
GlobalX is a new entrant airline now in FAA certification using the Airbus A320 family aircraft. Subject to FAA and DOT approvals, GlobalX intends to fly as an ACMI and wet lease charter airline serving the US, Caribbean and Latin American markets. For more information please visit https://www.globalairlinesgroup.com/.
Global Crossing Airlines provided an investor update on June 30, 2021. Over the past year, the company has achieved key milestones in its plan to launch as a US domestic and international airline, including completing FAA certification testing, recruiting an experienced leadership team, raising over $23 million, and signing aircraft lease and charter contracts. The update discusses the company's progress, future growth plans, and financial outlook.
About Global Crossing Airlines Group Inc.
Global Crossing is a U.S. 121 domestic flag and supplemental airline flying the Airbus A320 family aircraft. GlobalX flies as an ACMI (aircraft, crew, maintenance and insurance) and charter airline serving the U.S., Caribbean and Latin American markets.
GlobalX provides an overview of their business updates and growth plans. They operate a hybrid charter airline model with both passenger and cargo operations. GlobalX has seen strong growth in block hours and expects continued expansion in 2022. They plan to opportunistically acquire additional aircraft to capitalize on recovery in the passenger and cargo markets.
Global Crossing Airlines / GlobalX Corporate Presentation (JET: TSX-V; JETMF:...The Howard Group Inc.
Global Crossing Airlines is presenting at the 2021 Virtual Transportation & Logistics Conference. The summary discusses:
1) Global Crossing's original investment thesis was to enter the narrowbody charter market with modern aircraft at competitive prices, taking advantage of favorable leasing terms as the aircraft leasing market downturned.
2) COVID-19 significantly increased available aircraft and reduced lease rates while weakening competition and increasing the pool of available pilots and staff, improving Global Crossing's position.
3) Global Crossing aims to operate passenger charters and cargo flights, taking advantage of an opportunity in both markets as existing operators use very old aircraft. They have signed deals for aircraft and are progressing certification.
This document provides information about an initial public offering, including that a preliminary prospectus has been filed with securities regulators containing important information about the securities. The preliminary prospectus is still subject to completion and securities will not be sold until a receipt for the final prospectus has been issued. The document also advises that the preliminary prospectus should be read for full disclosure before making an investment decision.
The document provides an overview of Ero Copper's April 2022 analyst site visit to their MCSA Mining Complex and Boa Esperança project in Brazil. It includes forward-looking statements and cautions that actual results may differ materially from projections. It also notes the qualifications of the experts who prepared technical reports on the company's properties and provides context around non-IFRS financial measures discussed. Key topics to be covered include health, safety and environment; performance and growth opportunities at MCSA and NX Gold; updates on the Boa Esperança project; and the company's balance sheet and financial position.
Ero Copper held a technical session to discuss its 2022 exploration program and recent results. The session provided an overview of exploration activities across Ero's portfolio, including near-mine exploration and regional programs at the MCSA Mining Complex, nickel exploration, and work at the Boa Esperança and NX Gold projects. Ero aims to unlock value across all timescales through ongoing life-of-mine planning and exploration, with a focus on generating high-margin growth projects delivering high returns on investment.
Corporate presentation january 17, 2017 - finalcorpaveda2015
This document is a corporate presentation for Aveda Transportation and Energy Services Inc. regarding a preliminary short form prospectus offering of securities. It provides an overview of Aveda's history and operations, but cautions investors that the information is not comprehensive and that the securities have risks. It directs readers to the prospectus for full disclosure and includes standard disclaimers about forward-looking statements and non-IFRS measures.
This document provides an overview of Constellation Brands' investment in Canopy Growth Corporation and contains forward-looking statements regarding their business strategies, future operations, growth opportunities, and financial projections. It cautions that these statements are based on current expectations and actual results could differ due to various risk factors and uncertainties.
The document is a corporate presentation for Zenabis Global Inc. that provides an overview of the company's history and operations. It notes that Zenabis was formed in January 2019 through the reverse takeover of Bevo Agro Inc. by Sun Pharm Investments Ltd. Bevo Agro had a successful 30+ year history of growing hundreds of unique crops at an industrial scale in British Columbia, with EBITDA growing at 20% annually from 2011 to 2018 and EBITDA margins of around 24% in 2018. The presentation contains standard disclaimer language about forward-looking statements and the purpose of the document being for information only.
This document summarizes a potential business combination between Bespoke Capital Acquisition Corp. ("BCAC") and Vintage Wine Estates, Inc. ("VWE"). It outlines the attractive investment thesis for combining the companies, including VWE's experienced management team, track record of acquisitions, diversified business model, and strong financial profile. The transaction overview provides details of the proposed enterprise value of $691 million, use of proceeds to repay debt, and post-merger board composition.
Constellation Brands provides an overview presentation for investors on its 2Q'21 results. The presentation contains forward-looking statements regarding Constellation's investments in Canopy Growth and potential benefits. It discusses Canopy's opportunities for growth in international cannabis markets as well as future product development. However, the presentation notes that forward-looking statements are subject to risks and uncertainties that could cause actual results to differ from expectations.
Pathway Health is one of the largest providers of out-of-hospital pain management services in Canada. We own and operate nine community-based clinics across four provinces where our team of health professionals work together to help patients by using a variety of evidence-based approaches.
Corporate presentation november 2016 finalcorpaveda2015
This corporate presentation provides an overview of Aveda Transportation and Energy Services Inc. It discusses Aveda's history of growth through acquisitions and expansion across North America. The presentation highlights Aveda's diversified revenue base across major oil basins in the US and Canada, as well as its blue chip customer base. It also summarizes Aveda's capitalization, balance sheet, and North American operations footprint.
This document provides an overview and forward-looking statements for Constellation Brands. It discusses Constellation's investment in Canopy Growth Corporation and the anticipated benefits, including potential growth opportunities in global cannabis markets. The document also references Constellation's plan to optimize its wine and spirits portfolio, achieve targeted revenue growth and operating margins, and return $4.5 billion in cash to shareholders through fiscal year 2023. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ from projections.
This presentation is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination
between Bespoke Capital Acquisition Corp. (“BCAC”) and Vintage Wine Estates, Inc. (“VWE”) and related transactions (collectively the “Potential Transactions".
Real matters Investor Presentation - April 26 2017 redactedrealmatters2016
This document provides information about an initial public offering, including that a preliminary prospectus has been filed with securities regulators containing important information about the securities. The preliminary prospectus is still subject to completion and securities will not be sold until a receipt for the final prospectus has been issued. The document also advises that prospective investors should rely only on the information in the preliminary prospectus and refers readers to risk factors and other disclosures contained therein.
This document summarizes an investor presentation for MedReleaf Corp.'s initial public offering. Key points include that MedReleaf is offering shares at $9.50-$10.50 per share to raise approximately $100 million Canadian dollars, which will be used to expand their existing cannabis production facility, develop new products, and for general corporate purposes. Investors are warned to consider the risks disclosed in the prospectus and that forward-looking statements are based on estimates and assumptions. The presentation highlights MedReleaf's current operational success, low production costs, high market share, and near-term expansion plans.
GlobalX is a US 121 domestic flag and supplemental airline flying the Airbus A320 family aircraft. GlobalX has one A320 in revenue operations and has begun the process to add its A321 aircraft onto its certificate subject to FAA and DOT approvals. GlobalX has announced the delivery of its third and fourth aircraft deliveries in the second half of 2021. GlobalX flies as an ACMI and wet lease charter airline serving the US, Caribbean, and Latin American markets. For more information, please visit www.globalxair.com
Global Crossing Airlines (GlobalX) Investor Presentation - TSXV: JET / OTCQB:...The Howard Group Inc.
GlobalX is a new entrant airline now in FAA certification using the Airbus A320 family aircraft. Subject to FAA and DOT approvals, GlobalX intends to fly as an ACMI and wet lease charter airline serving the US, Caribbean and Latin American markets. For more information please visit https://www.globalairlinesgroup.com/.
Global Crossing Airlines provided an investor update on June 30, 2021. Over the past year, the company has achieved key milestones in its plan to launch as a US domestic and international airline, including completing FAA certification testing, recruiting an experienced leadership team, raising over $23 million, and signing aircraft lease and charter contracts. The update discusses the company's progress, future growth plans, and financial outlook.
About Global Crossing Airlines Group Inc.
Global Crossing is a U.S. 121 domestic flag and supplemental airline flying the Airbus A320 family aircraft. GlobalX flies as an ACMI (aircraft, crew, maintenance and insurance) and charter airline serving the U.S., Caribbean and Latin American markets.
GlobalX provides an overview of their business updates and growth plans. They operate a hybrid charter airline model with both passenger and cargo operations. GlobalX has seen strong growth in block hours and expects continued expansion in 2022. They plan to opportunistically acquire additional aircraft to capitalize on recovery in the passenger and cargo markets.
Global Crossing Airlines / GlobalX Corporate Presentation (JET: TSX-V; JETMF:...The Howard Group Inc.
Global Crossing Airlines is presenting at the 2021 Virtual Transportation & Logistics Conference. The summary discusses:
1) Global Crossing's original investment thesis was to enter the narrowbody charter market with modern aircraft at competitive prices, taking advantage of favorable leasing terms as the aircraft leasing market downturned.
2) COVID-19 significantly increased available aircraft and reduced lease rates while weakening competition and increasing the pool of available pilots and staff, improving Global Crossing's position.
3) Global Crossing aims to operate passenger charters and cargo flights, taking advantage of an opportunity in both markets as existing operators use very old aircraft. They have signed deals for aircraft and are progressing certification.
This document provides information about an initial public offering, including that a preliminary prospectus has been filed with securities regulators containing important information about the securities. The preliminary prospectus is still subject to completion and securities will not be sold until a receipt for the final prospectus has been issued. The document also advises that the preliminary prospectus should be read for full disclosure before making an investment decision.
The document provides an overview of Ero Copper's April 2022 analyst site visit to their MCSA Mining Complex and Boa Esperança project in Brazil. It includes forward-looking statements and cautions that actual results may differ materially from projections. It also notes the qualifications of the experts who prepared technical reports on the company's properties and provides context around non-IFRS financial measures discussed. Key topics to be covered include health, safety and environment; performance and growth opportunities at MCSA and NX Gold; updates on the Boa Esperança project; and the company's balance sheet and financial position.
Ero Copper held a technical session to discuss its 2022 exploration program and recent results. The session provided an overview of exploration activities across Ero's portfolio, including near-mine exploration and regional programs at the MCSA Mining Complex, nickel exploration, and work at the Boa Esperança and NX Gold projects. Ero aims to unlock value across all timescales through ongoing life-of-mine planning and exploration, with a focus on generating high-margin growth projects delivering high returns on investment.
Corporate presentation january 17, 2017 - finalcorpaveda2015
This document is a corporate presentation for Aveda Transportation and Energy Services Inc. regarding a preliminary short form prospectus offering of securities. It provides an overview of Aveda's history and operations, but cautions investors that the information is not comprehensive and that the securities have risks. It directs readers to the prospectus for full disclosure and includes standard disclaimers about forward-looking statements and non-IFRS measures.
This document provides an overview of Constellation Brands' investment in Canopy Growth Corporation and contains forward-looking statements regarding their business strategies, future operations, growth opportunities, and financial projections. It cautions that these statements are based on current expectations and actual results could differ due to various risk factors and uncertainties.
The document is a corporate presentation for Zenabis Global Inc. that provides an overview of the company's history and operations. It notes that Zenabis was formed in January 2019 through the reverse takeover of Bevo Agro Inc. by Sun Pharm Investments Ltd. Bevo Agro had a successful 30+ year history of growing hundreds of unique crops at an industrial scale in British Columbia, with EBITDA growing at 20% annually from 2011 to 2018 and EBITDA margins of around 24% in 2018. The presentation contains standard disclaimer language about forward-looking statements and the purpose of the document being for information only.
This document summarizes a potential business combination between Bespoke Capital Acquisition Corp. ("BCAC") and Vintage Wine Estates, Inc. ("VWE"). It outlines the attractive investment thesis for combining the companies, including VWE's experienced management team, track record of acquisitions, diversified business model, and strong financial profile. The transaction overview provides details of the proposed enterprise value of $691 million, use of proceeds to repay debt, and post-merger board composition.
Constellation Brands provides an overview presentation for investors on its 2Q'21 results. The presentation contains forward-looking statements regarding Constellation's investments in Canopy Growth and potential benefits. It discusses Canopy's opportunities for growth in international cannabis markets as well as future product development. However, the presentation notes that forward-looking statements are subject to risks and uncertainties that could cause actual results to differ from expectations.
Pathway Health is one of the largest providers of out-of-hospital pain management services in Canada. We own and operate nine community-based clinics across four provinces where our team of health professionals work together to help patients by using a variety of evidence-based approaches.
Corporate presentation november 2016 finalcorpaveda2015
This corporate presentation provides an overview of Aveda Transportation and Energy Services Inc. It discusses Aveda's history of growth through acquisitions and expansion across North America. The presentation highlights Aveda's diversified revenue base across major oil basins in the US and Canada, as well as its blue chip customer base. It also summarizes Aveda's capitalization, balance sheet, and North American operations footprint.
This document provides an overview and forward-looking statements for Constellation Brands. It discusses Constellation's investment in Canopy Growth Corporation and the anticipated benefits, including potential growth opportunities in global cannabis markets. The document also references Constellation's plan to optimize its wine and spirits portfolio, achieve targeted revenue growth and operating margins, and return $4.5 billion in cash to shareholders through fiscal year 2023. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ from projections.
This presentation is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to a potential business combination
between Bespoke Capital Acquisition Corp. (“BCAC”) and Vintage Wine Estates, Inc. (“VWE”) and related transactions (collectively the “Potential Transactions".
Real matters Investor Presentation - April 26 2017 redactedrealmatters2016
This document provides information about an initial public offering, including that a preliminary prospectus has been filed with securities regulators containing important information about the securities. The preliminary prospectus is still subject to completion and securities will not be sold until a receipt for the final prospectus has been issued. The document also advises that prospective investors should rely only on the information in the preliminary prospectus and refers readers to risk factors and other disclosures contained therein.
This document summarizes an investor presentation for MedReleaf Corp.'s initial public offering. Key points include that MedReleaf is offering shares at $9.50-$10.50 per share to raise approximately $100 million Canadian dollars, which will be used to expand their existing cannabis production facility, develop new products, and for general corporate purposes. Investors are warned to consider the risks disclosed in the prospectus and that forward-looking statements are based on estimates and assumptions. The presentation highlights MedReleaf's current operational success, low production costs, high market share, and near-term expansion plans.
This document summarizes an investor presentation for MedReleaf Corp.'s initial public offering. Key points include that MedReleaf is seeking to raise approximately $100 million Canadian dollars in an IPO priced between $9.50-$10.50 per share. Proceeds will be used to expand MedReleaf's existing cannabis production and manufacturing facilities, fund clinical research, and for general working capital purposes. The presentation highlights MedReleaf's current operational success and leadership in the Canadian medical cannabis market.
This document summarizes an investor presentation for MedReleaf Corp.'s initial public offering. It outlines key details of the offering such as the issuer, selling shareholders, offering price range between $9.50-$10.50 per share, expected size of $100 million, and intended use of proceeds. It also highlights MedReleaf's leadership in the Canadian medical cannabis market through its high quality indoor cultivation facilities, low production costs, revenue growth while maintaining profitability, and plans for expansion.
Progyny JP Morgan Presentation January 2023.pdfssuser5105e0
This document provides an overview of Progyny, a benefits company focused on fertility and family building. It discusses Progyny's mission-driven approach, data-driven network management, and track record of superior clinical outcomes. The document also reviews Progyny's growth, highlighting near 100% client retention and expanding coverage to over 5 million lives. It positions Progyny as the only fully-managed family building solution and discusses how its approach delivers tangible value through savings and healthier outcomes compared to alternative programs.
Avicanna is a biopharmaceutical company focused on developing and commercializing plant-derived cannabinoid-based products. They have a scientific platform and R&D capabilities for product development as well as commercial operations across 18 international markets. Their product portfolio includes over 20 proprietary formulations under their medical and wellness brand RHO Phyto as well as a pharmaceutical CBD drug preparation pending market authorization. Avicanna also has a pharmaceutical pipeline of cannabinoid-based drug candidates targeting neurological, dermatological and pain indications.
Q1 2015 earnings slides monday final reviewinvestorjgwpt
1) The document discusses the company's first quarter 2015 earnings call which reviewed financial results and key initiatives.
2) Total revenues were $62.4 million, adjusted net income was $8.2 million or $0.29 per share, and total receivables purchased were $260.8 million.
3) The company is focused on growing its core business while diversifying into new lines like prepaid and personal lending, and recently acquired a mortgage originator.
- WTW reported its 2021 fourth quarter and full year financial results on February 8, 2022.
- For Q4 2021, revenue increased 1% to $2.7 billion. Income from operations grew 19% to $690 million and operating margin expanded 380 basis points to 25.5%.
- For full year 2021, revenue increased 4% to $9 billion. Income from operations jumped 156% to $2.2 billion and operating margin grew 1450 basis points to 24.5%.
This management presentation discusses Sleep Country Canada's initial public offering. It provides an overview of the company as the leading specialty mattress retailer in Canada, with a national footprint and market leading brand recognition and traffic. The presentation highlights Sleep Country's best-in-class retail strategy focused on an unrivaled in-store customer experience through highly trained staff and superior home delivery. Financial highlights and growth targets are presented, noting the company's attractive financial model and ability to generate strong cash flow. Risk factors and forward-looking statements are also discussed.
1) CanniMed Therapeutics is an international, biopharmaceutical company and leader in the Canadian medical cannabis industry with pharmaceutical-grade products.
2) They have a 15-year history of growing medical cannabis and a first mover advantage in emerging international markets like Australia.
3) Recent results show strong revenue, volume, and EBITDA growth and they have expanded production capacity with government support. The Canadian and international medical cannabis markets provide significant opportunities.
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of evidence-based cannabinoid-based products for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development that has led to the commercialization of more than thirty products across various market segments:
Medical Cannabis & Wellness Products: Marketed under the RHO Phyto™ brand these medical and wellness products are a line of pharmaceutical-grade cannabinoid products containing varying ratios of cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”). The product portfolio contains a full formulary of products including oral, sublingual, topical, and transdermal deliveries that have controlled dosing, enhanced absorption and stability studies supported by pre-clinical data. The formulary is marketed with consumer, patient and medical-community education and training.
Canni med therapeutics inc management presentation - march 2017CannimedTherapeutics
CanniMed Therapeutics is a Canadian pharmaceutical company and leader in the medical cannabis industry with 15 years of experience culturing cannabis. It has a GMP-compliant production process with strict quality control and is conducting the first Health Canada approved Phase IIA clinical trial. CanniMed is focused on producing pharmaceutical-grade cannabis products and developing new delivery methods, such as cannabis oil gelcaps, to appeal to broader medical markets for pain treatment. It aims to address the large market for alternative chronic pain therapies and the needs of aging baby boomers.
The Health & Wellness market in the UK was valued at £23bn in 2020, an increase from £20.5bn in 2015. Total healthcare, wellness and fitness spending in the UK reached £209bn in 2020. Pure Restore Health provides innovative treatments and therapies utilizing the latest healthcare technologies to help people feel their best by addressing issues like chronic pain, injury recovery, athletic performance and more.
CanniMed Therapeutics Inc. is a leader in the Canadian medical cannabis industry and the first mover in international markets. It has a 15-year history of growing pharmaceutical-grade cannabis and is well positioned for growth through new distribution channels in Canada, increasing production capacity, and pursuing exports to multiple countries. Recent developments include strong Q3 2017 results, entering Canada's first pharmacy distribution agreement, and commencing an expansion of its Cannabis Oils Facility.
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. With modest cash burn and a strong balance sheet, including $142.4 million cash and cash equivalents as of June 30, 2023, Zomedica is well-positioned to fund both organic growth and acquisitions.
Aurora investor presentation acquisition of canni-med therapeuticsMarc Lakmaaker
- Aurora has acquired CanniMed Therapeutics to form a medical cannabis centre of excellence and gain CanniMed's drug delivery technologies and strong brands.
- The acquisition adds 19,000 kg per year of funded production capacity and expands Aurora's international footprint.
- The combination of Aurora and CanniMed enhances Aurora's medical offerings with CanniMed's four balanced ratio cannabis strains.
April 2018 Aurora Cannabis Investor Presentationhughcarter
- Aurora has acquired CanniMed Therapeutics to form a medical cannabis centre of excellence and gain CanniMed's drug delivery technologies and strong brands.
- The acquisition adds 19,000 kg per year of funded production capacity and expands Aurora's international footprint.
- Aurora aims to integrate CanniMed strategically to increase production capacity, drive international growth, develop new intellectual property, and accelerate patient registration.
Hemptown Spring 2019 Investor PresentationHemptown USA
From the rich soils of Southern Oregon's Emerald Triangle, Hemptown USA is producing some of the finest cannabinoid products in the world.
Hemptown USA’s toolkit is a unique one. Combined with our vertically integrated business model we are in firmly positioned to capitalize on a global market expected to exceed $22 billion by 2020.
JGW Business Overview – Jeffries Crossover Consumer Finance Summit investorjgwpt
The document discusses several non-GAAP financial measures used by the company, including Adjusted Net Income, Total Adjusted Revenue, Spread Revenue, and EBITDA. It provides definitions for each measure and notes they exclude amounts related to consolidated securitization trusts. The company uses these measures to evaluate performance excluding impacts of the trusts. It also provides an overview of the company's businesses in structured settlement purchasing, home lending, and plans for personal lending and prepaid cards. The goal is to diversify as a consumer financial services company through growth, cost savings, and new product lines.
About Temas Resources Corp.
The company is focused on the advancement of mineral independence and processes by which minerals are extracted in an environmentally friendly manner. The company invests in and works to apply green technology across its mining portfolio to reduce the environmental impact and carbon footprint of metal extraction through advanced processing and patented leaching technologies. The company is advancing iron-titanium-vanadium projects in Quebec and soon expects to be active at its boron projects in Serbia.
About Progressive Planet Solutions Inc.
Progressive Planet is an emerging company, providing innovative circular solutions and Earth-friendly micronized minerals that naturally unlock sustainability benefits across the construction and agriculture industries. Tapping into the Earth's inherent binding powers and properties, Progressive Planet is developing and scaling a portfolio of proprietary solutions to help its customers build, grow and operate more responsibly.
Progressive Planet continues work on creating supplementary cementing materials with a focus on minimizing the carbon footprint of the SCMs it creates, utilizing waste materials where possible to create the most sustainable SCMs and sequestering carbon dioxide in SCMs to address climate change. Progressive Planet's research team has begun exploring the opportunity to utilize the legacy CO2 stream generated by APL's natural gas rotary kiln dryer in operation in Kamloops.
Progressive Planet's operations currently include:
A comminution facility in Spallumcheen, B.C., which is currently producing micronized minerals used by farmers in lieu of chemical fertilizers to promote healthy soils without the addition of chemicals;
A research lab in Calgary, Alta., focused on creating SCMs and associated technologies to sequester CO2 in concrete;
Three natural pozzolan properties in British Columbia, including its flagship Z1 natural pozzolan quarry in Cache Creek, B.C., and its two pozzolan properties under development, the Z2 natural pozzolan property near Falkland and the Heffley Creek metal and natural pozzolan property.
The document provides an overview of Thesis Gold's Ranch Gold-Copper Project located in northern British Columbia. Key points include:
- The project covers over 18,000 hectares of underexplored land with over 20 historical precious metal occurrences.
- A 16,000 meter drilling program in 2021 aimed to confirm and expand on high-grade drill results including 19.6 g/t Au over 34 meters.
- Surface exploration including over 7,400 soil and 700 rock samples is ongoing to generate new targets.
- Initial drilling results from the Bonanza Zone were positive and confirmed high-grade gold mineralization over broad intervals.
Cematrix is a rapidly growing, cash-flow-positive company that manufactures and supplies technologically advanced cellular concrete products developed from proprietary formulations across North America. This unique cement-based material with superior thermal protection delivers cost-effective, innovative solutions to a broad range of problems facing the infrastructure, industrial (including oil and gas) and commercial markets. Through recent acquisitions of Chicago-based MOS and Bellingham-based Pacific International Grout, Cematrix is now North America's largest cellular concrete company.
Thesis Gold is a mineral exploration company focused on proving and developing the resource potential of the 17,832-hectare Ranch gold project located in the Golden Horseshoe area of Northern British Columbia, approximately 300 kilometres north of Smithers, B.C.
Cematrix is a leading provider of cellular concrete technology. The presentation provides an overview of Cematrix, including their focus on sustainability and proprietary technologies. It also outlines their growth strategy, which involves regional expansion, mergers and acquisitions, and strategic alliances. Cematrix has achieved major milestones and endured through a history in the industry since going public in 2006.
Thesis Gold is a mineral exploration company focused on proving and developing the resource potential of the 17,832-hectare Ranch gold project located in the Golden Horseshoe area of Northern British Columbia, approximately 300 kilometres north of Smithers, B.C.
Global Crossing Airlines (GlobalX) is the newest entrant to the charter/cargo space in the US. The company was created from a reverse takeover of Canada Jetlines in June 2020.
AirTest Technologies Inc. (TSX-V: AAT) is a rapidly-growing green tech company specializing in sensors that significantly improve commercial building operating efficiency. AirTest's leading-edge, proprietary sensor technologies improve the energy performance, environmental impact and return on investment for the millions of buildings we all work, shop and play in. We work with existing building contractors, building owners, property management companies, energy management companies and large equipment and controls manufacturers.
Drawing on innovations originating from the medical, electronics, telecommunication and automotive field, AirTest offers a growing portfolio of sensor products that meet the unique needs of the "buildings" industry along with application tools and cutting edge communication technologies that will ensure the easy and cost effective migration of these technologies to all buildings."
Thesis Gold is a mineral exploration company focused on proving and developing the resource potential of the 17,832-hectare Ranch gold project located in the Golden Horseshoe area of northern British Columbia, approximately 300 km north of Smithers, B.C. For further details about the Ranch Gold Project, please refer to the company's current geological technical report dated Sept. 18, 2020, available under the company's profile on SEDAR.
PLAN is developing technologies and materials to reduce the carbon footprint of cement production and create more sustainable concrete. Their flagship product, PozGlass SCM, aims to replace Portland cement by combining natural pozzolan with recycled glass to produce a supplementary cementitious material. This has the potential to sequester carbon dioxide during the curing process. If successful, PozGlass SCM could be used in most concrete applications like buildings and infrastructure, diverting waste glass from landfills. PLAN is also exploring using natural pozzolans and other products to sequester carbon in soil as a way to offset cement emissions.
1) Mineworx has developed a chemical process to extract precious metals like platinum and palladium from catalytic converters, providing a solution for recyclers currently unable to process diesel converters.
2) A pilot plant is being constructed and tested to optimize the process, with commercialization planned for late 2021.
3) The technology is expected to generate over $100 million in annual revenue from an initial commercial plant processing 10 tonnes per day, capturing a 20% gross margin.
This corporate presentation provides an overview of CEMATRIX, a leading on-site manufacturer and installer of cellular concrete. Some key points:
- CEMATRIX utilizes proprietary technologies to provide infrastructure construction solutions using cellular concrete, which is generally more sustainable than legacy products.
- They have a growing backlog exceeding $94M as of June 2021 and are focused on infrastructure projects benefiting from government spending.
- CEMATRIX has a strategic partnership with Lafarge, the largest global building materials company, providing supply agreements and joint marketing opportunities.
- Cellular concrete is lightweight, strong, and more environmentally friendly than traditional fills or insulations, making it a valuable construction material.
PLAN is developing technologies to reduce the carbon footprint of cement production and concrete. Their flagship product, PozGlass SCM, aims to replace Portland cement in concrete with a more sustainable blend containing natural pozzolan and recycled glass that can also sequester carbon dioxide. If successful, PozGlass SCM could divert waste glass from landfills while making concrete that is stronger and has a lower carbon footprint than conventional concrete. PLAN is also exploring using soil and other cement products to capture and store carbon dioxide from industrial emissions on a large scale.
PLAN is developing technologies to reduce the carbon footprint of cement production and concrete. Their flagship product, PozGlass SCM, aims to replace Portland cement in concrete with a more sustainable blend containing natural pozzolan and recycled glass that can also sequester carbon dioxide. If successful, PozGlass SCM could divert waste glass from landfills while making concrete that is stronger and has a lower carbon footprint than conventional concrete. PLAN is also exploring using soil and cement applications to permanently sequester additional carbon dioxide from industrial sources.
The presentation summarizes Thesis Gold's Ranch Gold Project located in British Columbia's Golden Horseshoe region. The Ranch Project covers over 178 square kilometers and contains 21 known near-surface epithermal gold deposits with historical drilling averaging less than 100 meters in depth. Thesis plans an aggressive 20,000 meter drilling campaign starting in July 2021 to further define resources across the property, where mineralization at existing zones remains open along strike and at depth. The team is experienced in the region and aims to rapidly delineate the substantial exploration potential through data compilation, geological mapping, geophysics, and an initial fully funded drill program.
Progressive Planet is developing technologies to decarbonize cement production, including PozGlass SCM and C-Quester Cellular Concrete. PozGlass combines natural pozzolan and recycled glass to reduce CO2 emissions in concrete, while C-Quester aims to permanently sequester CO2 in cellular concrete. Testing of PozGlass is underway, with commercial production planned for 2022 to replace fly ash and reduce the cement industry's environmental impact.
This corporate presentation from CEMATRIX provides an overview of the company and its cellular concrete technology. CEMATRIX manufactures and installs cellular concrete on site across North America using proprietary technologies. Cellular concrete is a more sustainable and environmentally friendly alternative to other materials like EPS blocks and rigid insulations. The presentation highlights CEMATRIX's strategic partnership with Lafarge, its growth strategy through acquisitions, and its focus on infrastructure, industrial, and commercial end markets.
- Company technology allows extraction of precious metals from diesel catalytic converters, solving issues smelters face with this feedstock.
- Letter of Intent signed with leading U.S. catalytic converter recycler to provide diesel converter supply for commercial plant.
- Engineering completed for pilot plant to process 10 tonnes/day, projected to generate $100M+ annually at commercial scale.
- Pilot plant fabrication underway and operational testing planned for Q3 2021 to optimize commercial plant design.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
Here is the updated list of Top Best Ayurvedic medicine for Gas and Indigestion and those are Gas-O-Go Syp for Dyspepsia | Lavizyme Syrup for Acidity | Yumzyme Hepatoprotective Capsules etc
Pathway Health Corp November 2021 Company Presentation
1. w w w . p a t h w a y h e a l t h . c a
Corporate Presentation
Pathway
Health
November 2021
2. Certain statements contained in this presentation constitute forward-looking statements. The words “anticipate”,
“continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions typically are used to
identify forward-looking statements. By their nature, forward-looking statements and information involve known and
unknown opportunities, costs, risks and uncertainties that may cause actual results to differ materially from those
anticipated. Except for statements of historical fact, certain information contained herein constitutes forward-looking
statements which include management’s assessment of future plans and operations and are based on current internal
expectations, estimates, projections, assumptions and beliefs, which may prove to be incorrect.
The use of forward-looking statements reflects our current views, expectations, estimates and/or projections with respect
to our performance, business and future events, and in this presentation includes statements relating to, among others:
expectations regarding our business; expectations relating to our business goals, objectives and schedules; expectations
regarding the cannabinoid based therapy industry, including Canada’s position therein; expectations regarding the
acceptance of cannabinoid based therapies in the medical community; expectations regarding our clinical development
plans; expectations regarding development of new intellectual property, including from cannabinoid product combinations;
expectations related to the anticipated closing of the subscription receipt offering and reverse take-over with a Capital Pool
Company; the terms and conditions of the subscription receipt offering; and the use of proceeds from the subscription
receipt offering. Forward-looking statements are prepared by management and based on the then-current expectations,
forecasts and assumptions about the business and the industry and markets in which we operate, including, among others:
that there will be no unforeseen delays, disruptions, market forces, regulations or laws that will prevent us from operating
our business; that we will be able to obtain the capital we require; that the subscription receipt offering has closed; that the
escrow release conditions in respect of the subscription receipt offering have been fulfilled; and that the reverse take-over
has been completed. Forward-looking statements are not guarantees of future performance and involve risks, uncertainties
and assumptions which are difficult to predict, including, without limitation: that we may experience unforeseen delays,
financing difficulties or costs that will impact our projects, operations, financial performance or liquidity; that we will not be
able to advance our business plan or continue operations; that we will not be able to obtain insurance for our operations;
that we will not be able to protect our intellectual property; that we will not be able to develop and commercialize, or
obtain regulatory approvals to commercialize, products derived from our intellectual property; that we will not be able to
recruit physicians for our clinics; that regulatory approvals of products developed from our intellectual property may result
in significant delays; that development of cannabinoid based therapies may expose us to liability claims in excess of our
insurance coverage; and those risks relating to the occurrence of national disasters, hostilities, acts of war or terrorism, our
reputation, our key personnel, competition, employee relations, changes in the cannabinoid based therapy market
generally, potential downturns in economic conditions, pandemics, foreign exchange fluctuations, fluctuations in the
currency markets, inflationary pressures, changes in interest rates, changes in regulatory requirements which may alter or
prohibit investment in our business, or changes in national and local government legislation, taxation, controls, regulations
and political or economic developments in Canada or any other country in which we operate or intend to operate.
These risks, as well as others, could cause actual results and events to differ materially from those anticipated in such
forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements and
information, which are qualified in their entirety by this cautionary statement. These statements speak only as of the date
of this presentation and we do not undertake any obligations to update such forward-looking statements, except as
required by applicable securities law.
To the extent any forward-looking information in this presentation constitutes “future-oriented financial information” or
“financial outlooks” within the meaning of applicable Canadian securities laws, such information is being provided to
demonstrate the potential benefits of the company’s business plans and strategies, and the reader is cautioned that this
information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-
oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with
forward-looking information generally, are, without limitation, based on the assumptions and subject to the risks set out
herein. The company’s results of operations and estimated and forecasted revenue may differ materially from
management’s current expectations. Such information is presented for illustrative purposes only and may not be an
indication of the company’s actual future results of operations or earnings.
Market and industry data contained in this presentation is based upon information, surveys or studies conducted by
independent third parties and independent industry or general publications and management’s knowledge of, and
experience in, the markets in which we operate or intend to operate. We have no reason to believe that such third-party
information is false or misleading in any material respect, however market and industry data is subject to variation and
cannot be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary nature
of the data gathering process and other limitations and uncertainties inherent in any statistical survey. This third-party
information has not been independently verified by us or any of our respective directors, officers or representatives and no
representation is given as to the accuracy of any of the data from third party sources referred to in this presentation.
The securities being offered pursuant to the subscription receipt offering are being offered on a private placement basis in
reliance upon prospectus and registration exemptions under applicable securities legislation. Resale of the securities offered
hereunder will be subject to restrictions under applicable securities legislation, which will vary depending on the relevant
jurisdiction. Generally, such securities may be resold only pursuant to an exemption from the prospectus and registration
requirements of applicable securities legislation or pursuant to an exemption order granted by appropriate securities
regulatory authorities.
The securities being offered pursuant to the subscription receipt offering have not, nor will they be, registered under the
United States Securities Act of 1933, as amended, or the securities laws of any state of the United States and may not be
offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S.
registration or an applicable exemption from the U.S. registration requirements. This presentation does not constitutes an
offer for sale of securities in the United States.
Forward Looking Statement
DISCLAIMER
3. 3
Pathway Health is an integrated healthcare
company that provides advanced products
and services to patients suffering from chronic
pain and related conditions.
Who We Are
4. 4
Investment Highlights
Largest medical cannabis service provider in Canada
Leading partner with Canadian pharmacy
companies for medical cannabis consultations,
pharmacist education
• Signed agreements covering ~2,000 retail
pharmacy locations nationally
• Cannabis Health Products (CHPs) development
• CHPs market estimated >$2 billion in 2022
• Proprietary, national distribution network
One of the largest providers of chronic pain services
in Canada
3-year revenue growth - $600k (2018) to $12.6
million (2020) 1
Investment
1. These are unaudited revenue figures. The revenue figures include management's best
estimate of additional revenue in relation to the acquisition of NHS, NACM Clinic and Pharmacy
business and NMI as if it happened January 1, 2020.
• ~65,000 active patients
5. 5
Our Business
Medical Cannabis
• Largest provider of medical
cannabis services in Canada
• >65,000 active patients
• Exclusively through telemedicine
• Partnering with all the top LPs
• Agreements with >2K pharmacies
Interdisciplinary chronic
pain management
• Comprehensive list of pain services
• Interventional
• Adding allied health (physio,
chiro, massage therapy)
• Expansion to include mental health
Home and Personal
Healthcare Products
• Products supporting lifestyles of
people with chronic pain
• Orthotics, canes, wheelchairs,
braces, home assist devices
• Sold through Slawner Ortho (PQ)
Cannabis Health Products
(CHPs)
• New consumer product market
• Potential size >$2 billion by 2023
• Working with pharmacies to
develop products
• Distribution network for a multi
billion-dollar product category
SERVICES PRODUCTS
Patients to be connected to products, services and more through My Spark app (under development)
6. 6
The Opportunity
Partnering
Opportunities
Workers Comp, unions, insurance
companies, family medical practices,
allied health, mental health, LPs, First
Nations, government, clinical trials
Fragmented
chronic pain industry
Opportunity to roll up industry - accretive
acquisitions to build on existing infrastructure
Pharmacy
Partnerships
Patient assessments for medical cannabis;
Cannabis Health Products (CHPs)
development and distribution
CHPs & Cannabis 3.0
Focus on medical - including CHPs;
Building CHPs product category with
pharmacy partners – proprietary
distribution network for a new, multi
billion-dollar product category
7. 7
Cannabis 3.0 and Canadian Pharmacies
Cannabis 3.0 - Bringing the benefits of cannabis derivatives (e.g. CBD) into
mainstream health products
NPA’s 1 pitch to the CDN government – “(P)harmacists have an important
role in providing clinical information to patients at the point of sale.”
January 2021
Pharmacies have limited or no experience with this new consumer
packaged goods category
PHC is a credible partner for pharmacies – medical/scientific foundation,
expertise in medical cannabis, strong ecosystem for product
development
1. NPA – Neighbourhood Pharmacy Association
In mid-2019, the federal government launched a consultation to seek
feedback on the introduction of a new category of health products with
cannabis, referred to as Cannabis Health Products (CHPs). If implemented,
this regime would have the potential to create a new market for cannabis
products in Canada.
8. What has been the
pharmacy industry’s
position on cannabis & CHPs?
8
As medication experts, pharmacists are best equipped to provide clinical advice to
patients & appropriate oversight in the safe management and dispensing of medical
cannabis.
Pharmacist management and dispensing of medical cannabis is the best option to
strengthen any future framework and protect patient and public safety.”
Canadian Pharmacists Association
Canadian
Pharmacists
Association
Canadian Pharmacists Association
April 2016
9. 9
Ontario College of Pharmacists
“As medication therapy experts, pharmacists are in a unique
position to provide quality and effective patient care for those
who consume cannabis. This may take place through educating
patients about the consumption of cannabis … and through
collaboration with other health care professionals to enhance
patient safety.
(T)he Ontario College of Pharmacists would not oppose any federal
or provincial legislation that would permit the dispensing of non-
smoked forms of cannabis for medical use within pharmacies...”
August 2016
10. 10
Evolution of Pharmacy & Cannabis (04/17 – 05/19)
Intro of Bill C-45
04/17
OCP Task Force releases
Cannabis Position Paper
05/18
Pathway signs deal with
Lovell Drugs
03/19
OCP endorses Cannabis
Position Paper
06/18
Cannabis legalized in
Canada
10/18
OCP requires
pharmacists to
complete cannabis
education
05/19
OCP establishes task
force on cannabis
09/17
Shoppers begins
cannabis sales online
01/19
Federal Government Pharmacy Pathway Health
OCP - Ontario College of Pharmacists
11. 11
Evolution of Pharmacy & Cannabis (05/19 - present)
Public consultation
on potential market
for CHPs
05/19
Cannabis
2.0 released
10/19
Pathway signs deal
with Sobeys
07/21
First brick & mortar
cannabis pharmacy
opens in Ottawa
06/20
NPA Medical Cannabis
Position Statement
released
01/21
Cannabis 3.0 released
?/22
Pathway’s Cannabis &
Patient Care for
Pharmacists course
given accreditation
08/19
Pathway signs deal with
PharmaChoice
06/21
Federal Government Pharmacy Pathway Health
CHPs – Cannabis Health Products | NPA - Neighbourhood Pharmacy Association
Pathway Health has been working alongside the pharmacy industry for 3
years preparing for Cannabis 3.0
12. 12
Pharmacy Agreements
Collaborating with pharmacy partners on
two iniatives:
• Education and certification of
pharmacists in cannabis
• Medical cannabis consultations for their
patients
Medical cannabis consultations from
pharmacies:
• >11K licensed pharmacists in CDA 1
• Approx. 1 in 5 Cdns over 15 have
used cannabis in last 3 months 2
• Product (CHPs) development in
discussion
Agreements in place with 6 pharmacy chains covering ~ 2,000 Canadian Pharmacies
1. https://napra.ca/national-statistics
2. https://globalnews.ca/news/5233154/cannabis-statistics-canada-survey/
13. 13
Bringing CHPs to Pharmacies
1. https://chfa.ca/en/regulatory/CBD-Economic-Report
2. https://mjbizdaily.com/chart-week-profit-margins-infused-products-can-sky-high/
3. https://napra.ca/national-statistics
In discussions with pharmacy partners regarding
development, branding and distribution of CHPs
through retail pharmacy locations across
Canada
Product portfolio to leverage advanced
delivery technologies (e.g. extended
release, rapid onset, etc.)
Forecast legal changes to CBD market
worth $2.3 billion by 2023 1
Profit margins can be higher than the
average for other consumer goods such as
alcohol, beer, wine, soft drinks and
cigarettes 2
Canada has approximately 43,600
licensed pharmacists working in more
than 11,400 pharmacies 3
14. 14
Chronic Pain – A Large and Growing Problem
1 Schopflocher et al., 2011; Reitsma et al., 2011; Steingrimsdottir et al., 2017, Canadian Pain Task Force Report, June 2019
2 https://www.benefitscanada.com/benefits/health-benefits/chronic-pain-costs-employers-52439
3 http://www.canada.com/health/live+this+life+pain+Canadians+with+chronic+pain+struggling+find+help+hope/5485154/story.html
>$50 billion in health care resources
and productivity losses 2
Burdensome
1-3 Years average wait time for
treatment at publicly-funded pain
clinics in Canada 3
Under capacity
1 in 5 Canadian adults experience
chronic pain 1
Prevalent
Specialized pain services are largely
inaccessible
Lack of specialists
15. 15
Clinic Growth Plans
Current 9 locations include Toronto, Montreal (3),
Chateauguay, Magog, Saskatoon, Winnipeg, Selkirk
• Goal is to establish a national footprint
through M&A and partnerships
• Adding allied health services (physio, chiro,
massage therapy)
• Adding mental health
Expansion of telemedicine services through M&A
16. 16
Growth Drivers
Sign additional pharmacy agreements for new
patient consultations, education
New pharmacy agreements on CHPs – development,
distribution and co-branding
Regional market expansion of clinics in Canada
Continue rollup of patients and select clinics
Expand new clinical services to existing clinics
Medical Sales License for B2B and B2C sales
Growth Drivers
17. 17
Financial Overview
1. Gross margins on Provincial Billings expected to increase as further integration of recent acquisitions occurs.
2. These are unaudited revenue figures. The revenue figures include management's best estimate of additional revenue in relation to the acquisition of NHS, NACM Clinic and Pharmacy business
and NMI as if it happened January 1, 2020.
Education and marketing revenue
100% gross margins
LP Revenue
$3.9
Physician billings
20% gross margins1
Provincial Billing
$5.9
Patient private pay
80% gross margins
Non-Insured Billing
$0.5
$0.6
$6.6
$12.6
$0.0
$2.0
$4.0
$6.0
$8.0
$10.0
$12.0
$14.0
1
Quebec orthopaedic sales
70% gross margins
Product Sales
$2.2
Revenue (C$MM)2
31.4%
46.8%
17.8%
4%
2020 Revenue Contribution
2018 2020
2019
Provincial Billing
LP Revenue
Product Sales
Non-Insured Billing
18. 8.3 8.3
5.7
8.2
1.7 1.7
-
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
9.0
TEV/REV CAP/REV
Mean Median Pathway Health
18
Industry Comparable 1 2
1. Stock prices dated November 5, 2021
2. Based on reported 2020 financials
Industry Comparable
Akumin Inc.
Carebook Technologies Inc..
CloudMD Software and Services Inc.
Empower Clinics
Greenbrook TMS Inc.
Jack Nathan Health
MCI OneHealth
Medical Facilities Corp.
MindBeacon Holdings Inc.
Neupath Health Inc.
Skylight Health
ThinkResearch (TRC Holdings)
VitalHub Corp
WELL Health Technologies
19. 114,035,313 fully diluted shares outstanding. No derivative securities have an exercise price less than issue price of $0.50 per share 19
Cap Structure
Percentage Shares
Investor Group Ownership Outstanding
Insiders 55.7% 52,171,818
Other shareholders 44.3% 41,475,267
GRAND TOTAL 100% 93,647,085
20. Summary
20
Leading partner with Canadian Pharmacies on Medical Cannabis
1. These are unaudited revenue figures. The revenue figures include management's best estimate of additional revenue in relation to the acquisition of
NHS, NACM Clinic and Pharmacy business and NMI as if it happened January 1, 2020.
Signed 6 agreements with some of the nation’s largest retail pharmacies > becoming the leading partner for pain
products and services for thousands of Canadian pharmacies
In discussion with several national pharmacy companies on CHP development, branding and distribution in
preparation for Cannabis 3.0
Largest out-of-hospital chronic pain clinic in Canada
One of the leading and most comprehensive out-of-hospital pain management businesses in Canada
6 acquisitions since January 2019
Revenue has grown from $600K to almost $12 million in 3 years. 1
Developing a unique IT platform allowing the company to scale pharmacy initiative and expand its telemedicine
services
Proven management
Expertise and experience in healthcare, cannabis, M&A, capital markets